The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2025 | The future role of active surveillance in pancreatic neuroendocrine tumors
Stefano Partelli, MD, Vita-Salute San Raffaele University, Milan, Italy, comments on the management of asymptomatic pancreatic neuroendocrine tumors (PanNETs), suggesting that active surveillance should be considered first. However, in rare cases with signs of aggressiveness, such as dilatation of the main pancreatic duct, where surgery is recommended. Active surveillance is a safe approach for most patients, and the protocol used in the ASPEN study (NCT03084770) allowed for timely intervention in cases of early progression. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Well the best imaging modality is MRI because of the need to perform many of these imagings during the follow-up so in order to avoid the exposure of the patients to the x-rays. Again the only sign that should be considered a warning sign is the dilatation of the pancreatoduodenal or pancreatic duct, more commonly referred to as the ampulla or the pancreatic duct, however the term used was medipancreatic duct, a more precise term is the main pancreatic duct...
Well the best imaging modality is MRI because of the need to perform many of these imagings during the follow-up so in order to avoid the exposure of the patients to the x-rays. Again the only sign that should be considered a warning sign is the dilatation of the pancreatoduodenal or pancreatic duct, more commonly referred to as the ampulla or the pancreatic duct, however the term used was medipancreatic duct, a more precise term is the main pancreatic duct. We observed that some patients had already presented this type of feature, this dilatation, and other patients developed dilatation during the follow-up. So the first sign to look at is this and the second of course is the tumor growth. When the tumor increases in size and particularly when it reaches two centimeters or above then it’s time for surgery.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
